Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Mild Cognitive Impairment Market size was over USD 2.2 billion in 2024 and is estimated to reach USD 4.4 billion by the end of 2037, expanding at a CAGR of 6.1% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of mild cognitive impairment is evaluated at USD 2.3 billion.
The rising prevalence of Alzheimer’s disease across the world has become a public health concern, ensuring continuous demand in the mild cognitive impairment market. According to a report published by Alzheimer’s Disease International, the number of patients with this disease worldwide was counted to be more than 55 million in 2020. The report further estimated this number to become 78 million in 2030 and 139 million in 2050, doubling every 20 years. It also mentioned that globally around 10 million people are affected by dementia each year. Being an indicative medical condition of this disease, MCI and dementia are now being prioritized for early-stage treatment, assuring better patient outcomes.
The increasing rate of incidences has further dragged the focus of pharmaceutical companies to invest in the mild cognitive impairment market. The proven efficiency of genomic medicine in offering better treatment options has revolutionized this sector. Thus, the expansion of this pharma category is evidence of innovations in the MCI field. According to a Research Nester report, the genomics industry is expected to reach USD 259.4 billion by 2037, augmenting a CAGR of 15.3%. It is progressing to reach USD 45.7 billion in 2025. In addition to this, many healthcare organizations are also proactively promoting this industry for routine clinical use. According to a 2022 report from NHS England, the NHS delivered more than 100,000 genome projects in association with Genomics England.
Mild Cognitive Impairment Sector: Growth Drivers and Challenges
Growth Drivers
- Supportive government and regulatory framework: Besides promoting available treatment options, the governing authorities also significantly contribute to the progress of the mild cognitive impairment market. They are offering support to this sector by issuing favorable and subsidiary policies for pharma manufacturers and research institutions. They are also easing and fastening the process of new therapeutic launches with accelerated approvals. For instance, in January 2023, the U.S. Food and Drug Administration granted the application for marketing Leqembi (lecanemab-irmb) through the Accelerated Approval pathway for Alzheimer’s disease treatment.
- Growing awareness about early intervention: Another prominent contributor to the mild cognitive impairment market is the widespread knowledge about these diseases. Many private collaborations are also taking an active part in educating consumers about the importance of early treatment and diagnosis by captivating a wider audience in this sector. For instance, in November 2024, Eisai Co., Ltd. and Biogen Japan Ltd. teamed up to commence a nationwide awareness program by broadcasting educational TV commercials for MCI in Japan. Such awareness activities also attract other pharma leaders to invest in this sector, bringing diversity in available options, widening the product line.
Challenges
- Absence of universal diagnostic standards: The lack of definite diagnostic criteria is a major setback in the mild cognitive impairment market. This inconsistency often makes it difficult for healthcare service providers to avail fast and appropriate treatment solutions for patients with MCI. Moreover, the difficulty in identification may hamper the effectiveness of the therapeutics, declining consumer trust in these offerings and interest of pharma companies in drug development.
- Costly and complex treatments: Utilizing available products from the mild cognitive impairment market often becomes difficult for patients to afford. The Additional costs of managing accompanied comorbid conditions such as depression, anxiety, and cardiac diseases may make these treatments more complex and expensive. Thus, many patients, particularly from low-income regions mostly refrain from adopting them, limiting consumer base and profit margins.
Mild Cognitive Impairment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.1% |
|
Base Year Market Size (2024) |
USD 2.2 billion |
|
Forecast Year Market Size (2037) |
USD 4.4 billion |
|
Regional Scope |
|
Mild Cognitive Impairment Segmentation
Disease Type (Amnestic MCI, Non-Amnestic MCI)
Based on disease type, amnestic MCI segment is likely to capture mild cognitive impairment market share of over 61.4% by 2037. The heightened risk of developing more serious conditions such as Alzheimer’s Disease and Parkinson's disease dragged the focus of a major part of healthcare investors. In addition, the frequent prevalence of these MCI subtypes is highly prioritized in this sector. According to a survey conducted by NLM in the aged population of South Italy, in March 2022, the prevalence of amnestic MCI in people aged 60 or over was higher (7.4%) than non-amnestic MCI (4.6%). Thus, the enlarging global elderly population is increasing the risk of such cases, fueling demand in this segment.
Age (Child, Adult, Geriatric)
In terms of age, the geriatric segment is projected to dominate the mild cognitive impairment market by the end of 2037. The emphasized population of geriatric patients across the world has significantly added to the rise of this segment. According to a WHO report, released in October 2024, the number of people aged 60 or over is predicted to surpass 1.4 billion by 2030 from 1 billion in 2020. The report further estimated this population to double by 2050, accounting for 2.1 billion and the global population of 80-year-old citizens to reach 426 million. These growing numbers resemble the threat of the rise in worldwide AD cases, presenting a huge consumer base for this sector.
Our in-depth analysis of the global mild cognitive impairment market includes the following segments:
|
Disease Type |
|
|
Age |
|
|
Indication |
|
|
Treatment |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMild Cognitive Impairment Industry - Regional Synopsis
North America Market Analysis
The North America mild cognitive impairment market is predicted to obtain the largest share of 45.4% during the forecast period, 2025-2037. Its inflated economic burden due to healthcare expenditures on the aging population is pushing the authorities and pharma leaders to focus on development in this sector. According to an NLM report, the number of 65 or over years aged Alzheimer's dementia patients in America was 6.9 million in 2024 and is estimated to be 13.8 million by 2060. It further calculated the total value of unpaid dementia care services to be USD 346.6 billion in 2023 and the cost of healthcare in these cases (for 65 years or older) to reach USD 360 billion in 2024.
The U.S. is leading the regional mild cognitive impairment market with its strong emphasis on pharmaceutical R&D. The ongoing developments of genomic medicines in this country made it a strong contender among the major contributors of this sector. For instance, in July 2023, a team of scientists at Johns Hopkins Medicine introduced a potentially effective detection solution, NPTX2 for MCI. The newly unveiled protein can be a revolutionary indicator reagent in the field of early diagnosis by predicting cognitive impairment years before the first appearance of symptoms.
Canada is propelling its domestic mild cognitive impairment market by allocating notable funding and grants in elderly healthcare. The investments made by the governing bodies of this country supported this sector as a financial cushion. For instance, in February 2023, the government of Canada released a subsidy of USD 198.6 billion over 10 years to improve healthcare quality and access for senior citizens. Additionally, they announced another USD 1.7 billion fund over 5 years to strengthen the delivery system of home care or long-term care (LTC), dedicated to this aging population.
APAC Market Statistics
Asia Pacific is estimated to register the highest CAGR in the mild cognitive impairment market during the forecasted period. With the large pharmaceutical powerhouses, China & India and MedTech leader, Japan this region has set its goal to achieve adequate healthcare infrastructure to cope with the rising MCI prevalences. They are utilizing technological advancements to extend the production of effective medications and diagnostic tools to increase availability in this sector. Additionally, the promotional activities across the region to grow awareness among patients about non-pharmacological treatments and health monitoring products by incorporating digital patient-engaging solutions.
India is one of the pioneers in introducing new treatment solutions in the mild cognitive impairment market. By addressing the severity impact of delayed or improper diagnosis of transitioning phases and risk factors of AD, the country is focusing on developing innovative detection systems. For instance, in October 2021, the Indian Council of Medical Research Department of Health Research (ICMR) launched a consortium of neurocognitive tools, MUDRA Toolbox for dementia patients. The multilingual (Hindi, Bengali, Telugu, Kannada, and Malayalam) toolbox delivers sensible evaluations of early signs of Alzheimer’s and related disorders.
China is also a crucial participant in the consortium of innovations in the mild cognitive impairment market. Its R&D capabilities in the pharmaceutical industry have commendably contributed to the clinical developments in this field. Its remarkable engagement in drug discoveries has opened new opportunities for the domestic leaders in this sector. For instance, an NLM article revealed that the industrial pharmaceutical manufacturing firms in China spent USD 8.3 billion on research and experimentation in 2019, increasing by 75.3% from 2013. This amount covered the cost of 122,720 R&D personnel and 32,296 development projects across the country in the same year.
Companies Dominating the Mild Cognitive Impairment Landscape
- Johnson & Johnson Services, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Novartis AG
- AbbVie Inc.
- Biogen Japan Ltd.
- Aurobindo Pharma
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Taj Pharmaceuticals Ltd.
- Eli Lilly and Company
- Green Bioactives Ltd.
Key players in the mild cognitive impairment market are pushing their boundaries to expand their territory in the globalized landscape. They are empowering the untapped aspects of MCI to consolidate their position in this field. In addition, the integration of digital solutions has helped them introduce more convenient and affordable tools for disease management and early prevention. For instance, in November 2022, Roche Diagnostics launched automated cerebrospinal fluid (CSF)-based tests, the Elecsys ß-Amyloid (1-42) CSF, Elecsys Phospho-Tau (181P) CSF assays, and Elecsys Total -Tau CSF in India. These assays are designed to offer early and accurate diagnosis for AD patients. Such key players include:
In the News
- In July 2024, Eli Lilly and Company received FDA approval for marketing Kisunla as a treatment option for early symptomatic Alzheimer's disease in adults. The amyloid plaque-targeting therapy is comparatively an affordable option for patients suffering from MCI and dementia, requiring fewer infusions.
- In May 2024, Green Bioactives announced positive results of a clinical study on the efficacy of its newly launched GBL-Memory1, having cognitive benefits. The memory-boosting nutraceutical product showcased a promising scope for the company in capturing the MCI treatment market in the UK and Germany.
Author Credits: Radhika Pawar
- Report ID: 7049
- Published Date: Jan 27, 2025
- Report Format: PDF, PPT
